Skip to main content

A researcher works in a COVID-19 laboratory in Pernambuco, Brazil on June 30, 2020. A vaccine made in association with AstraZeneca is being tested in Brazil and South Africa after successful trials in the UK.

Andrea Rego Barros/Reuters

Early-stage human trial data on a vaccine being developed by AstraZeneca and Oxford University will be published on July 20, The Lancet medical journal said on Wednesday.

The vaccine candidate is already in large-scale Phase III human trials to assess whether it can protect against COVID-19, but its developers have yet to report Phase I results which would show whether it is safe and whether or not it induces an immune response.

“We expect this paper, which is undergoing final editing and preparation, to be published on Monday, July 20, for immediate release,” a spokeswoman for the journal said.

Story continues below advertisement

The Lancet’s statement came after reports earlier on Wednesday that the Phase I data could be released as soon Thursday.

Developers of the vaccine, known as known as AZD1222, said earlier this month they were encouraged by the immune response they had seen in trials so far and were expecting to publish Phase 1 data by the end of July.

A preclinical trial of the shot in pigs showed that two doses produced a greater antibody response than a single dose.

More than 100 vaccines are being developed and tested around the world to try to stop the COVID-19 pandemic, which has killed hundreds of thousands and ravaged the global economy.

The World Health Organization’s chief scientist said in June that AstraZeneca’s AZD1222 was probably the most advanced in terms of development.

The company has signed agreements with governments around the globe to supply the vaccine should it prove effective.

Researchers in the United States reported on Tuesday that Moderna Inc’s experimental vaccine showed it was safe and provoked immune responses in all 45 healthy volunteers in an ongoing early-stage study.

Story continues below advertisement

Moderna started its Phase II trial in May and expects to start a Phase III trial on July 27.

Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.

Coronavirus information
Coronavirus information
The Zero Canada Project provides resources to help you manage your health, your finances and your family life as Canada reopens.
Visit the hub
Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies